Contraindicated (1)bortezomib will improve the stage or outcome of mavacamten by influencing hepatic enzyme CYP2C19 metabolism. Contraindicated. Robust or reasonable CYP2C19 inhibitors may perhaps improve mavacamten systemic exposure, leading to heart failure as a consequence of systolic dysfunction. Drug Formulary information is intended for use by healthcare professionals. It is https://elliotdxqlc.dgbloggers.com/27145953/top-cp-866087-secrets